Trade with Eva: Analytics in action >>

Tuesday, August 8, 2017

Bellicum Pharma (BLCM) reported earnings on Tue 8 Aug 17 (a/h)

** charts before earnings **


 




** charts after earnings **





Bellicum Pharma misses by $0.08, misses on revs
  • Reports Q2 (Jun) loss of $0.74 per share, $0.08 worse than the Capital IQ Consensus of ($0.66); revenues were nil vs the $0.08 mln Capital IQ Consensus.
  • Enrollment in the pivotal EU BP-004 trial remains on track for completion by the end of 2017. Bellicum expects to initiate an observational trial in pediatric patients receiving transplants from matched unrelated donors (MUD) without BPX-501 in the third quarter. Outcomes from these trials are expected to be the basis for filings of European Marketing Authorization Applications for BPX-501 and rimiducid. The Company expects to report top-line results of these studies in the second half of 2018, with MAA filings planned for 2019.
  • Bellicum is finalizing plans for the design of registrational trials of BPX-501 in the U.S. The Company's current plans include conducting a controlled clinical trial in adult patients with acute myeloid leukemia (AML), which it expects to fund in part through its $16.9 million Product Development Award from the Cancer Prevention and Research Institute of Texas ("CPRIT"). In the pediatric non-malignant setting, Bellicum is designing a registrational trial to evaluate BPX-501 in a distinct subset of orphan inherited blood disorders.
  • As of June 30, 2017, cash, restricted cash and investments totaled $139.0 million. Based on current operating plans, Bellicum continues to expect to end 2017 with approximately $85 to $95 million in cash and investments, and that current cash resources will be sufficient to meet operating requirements through 2018.

No comments:

Post a Comment